REGENXBIO (NASDAQ:RGNX) Given “Equal Weight” Rating at Barclays

Barclays reissued their equal weight rating on shares of REGENXBIO (NASDAQ:RGNX) in a report issued on Friday, Marketbeat reports. They currently have a $12.00 price objective on the biotechnology company’s stock.

Several other research firms have also recently weighed in on RGNX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of REGENXBIO in a research report on Monday, June 8th. Robert W. Baird increased their target price on REGENXBIO from $27.00 to $32.00 and gave the stock an “outperform” rating in a research report on Monday, June 22nd. Morgan Stanley set a $16.00 target price on REGENXBIO in a research note on Friday, May 15th. HC Wainwright restated a “buy” rating and set a $26.00 price target on shares of REGENXBIO in a research report on Wednesday, July 1st. Finally, Zacks Research cut REGENXBIO from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $24.00.

REGENXBIO Trading Down 5.0%

NASDAQ:RGNX opened at $10.72 on Friday. The company has a 50-day moving average price of $10.02 and a 200-day moving average price of $9.43. REGENXBIO has a 12 month low of $5.45 and a 12 month high of $16.19. The stock has a market cap of $554.22 million, a price-to-earnings ratio of -2.83 and a beta of 0.94.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.35. REGENXBIO had a negative net margin of 112.58% and a negative return on equity of 220.07%. The company had revenue of $108.02 million for the quarter, compared to analysts’ expectations of $97.63 million. Equities analysts forecast that REGENXBIO will post -3.69 EPS for the current fiscal year.

Insiders Place Their Bets

In other REGENXBIO news, insider Steve Pakola sold 36,725 shares of REGENXBIO stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the transaction, the insider owned 213,009 shares in the company, valued at approximately $2,739,295.74. The trade was a 14.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 73,803 shares of company stock worth $886,937. 14.22% of the stock is owned by company insiders.

Hedge Funds Weigh In On REGENXBIO

Institutional investors and hedge funds have recently modified their holdings of the stock. Versant Capital Management Inc grew its position in REGENXBIO by 60.4% during the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 1,032 shares during the last quarter. Aquatic Capital Management LLC purchased a new position in REGENXBIO in the third quarter worth about $37,000. Captrust Financial Advisors bought a new position in shares of REGENXBIO in the second quarter worth approximately $85,000. Entropy Technologies LP bought a new position in shares of REGENXBIO in the first quarter worth approximately $87,000. Finally, Prudential Financial Inc. purchased a new stake in shares of REGENXBIO during the second quarter valued at approximately $87,000. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Strong Q2 results: REGENXBIO reported earnings of $0.43 per share, well above analyst estimates of $0.08–$0.12, while revenue of $108.0 million exceeded the $97.6 million consensus estimate. The result compares with a $1.38-per-share loss in the year-ago quarter. REGENXBIO Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Key pipeline milestones remain on track: The company said its RGX-202 gene therapy filing for Duchenne muscular dystrophy is expected to begin in the third quarter of 2026, with potential accelerated approval in the second half of 2027. RGX-121 for Hunter syndrome is also targeted for resubmission in Q3 2026, while pivotal wet age-related macular degeneration data are expected in Q4 2026. REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
• Positive Sentiment: Improved financial flexibility: More than $200 million of new capital raised in July increased pro forma cash, cash equivalents and marketable securities to over $310 million and extended the cash runway into the fourth quarter of 2027. This reduces near-term financing pressure as the company advances its programs. REGENXBIO Outlines Cash Runway
• Neutral Sentiment: Barclays maintained an Equal Weight rating and set a $12 price target, implying potential upside from recent trading levels but signaling a balanced view rather than a strong bullish recommendation. Barclays Rating Update
• Negative Sentiment: Profitability remains weak: Despite the quarterly beat, REGENXBIO continues to report a deeply negative net margin and return on equity, and analysts expect a full-year loss. Investors may therefore view the earnings improvement as less durable if it depends on licensing or other non-recurring revenue.
• Negative Sentiment: Material execution risk remains: The stock’s valuation and future upside depend heavily on successful regulatory filings, clinical data and eventual commercialization of its gene-therapy programs. Delays, safety concerns or disappointing trial results could pressure RGNX.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical?stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno?associated virus) platform. The company engineers next?generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age?related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.